While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

The price you pay for Beyfortus may depend on factors such as your child’s dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Beyfortus.

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

Q4 2024 Management View Paul Hudson highlighted significant progress in 2024 towards becoming a focused science-driven ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: ...

Lehi Free Press “This year has been particularly bad for the flu. We haven’t had a season quite this bad for a couple of ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...